Pharming Group Appoints Kenneth Lynard as Chief Financial Officer

Pharming Group N.V. has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard has over 20 years of experience in the life sciences industry and has held leadership positions at companies such as Gilead Sciences, Affidea, and Schoeller Allibert. He will focus on strengthening the company's financial leadership and supporting its growth strategy. Pharming Group N.V. is a global rare disease company with a strong growth momentum and upcoming commercial and pipeline catalysts.

Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) has announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Lynard, a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, will focus on strengthening the company's financial leadership and supporting its growth strategy [1].

Lynard's extensive career includes holding leadership positions at companies such as Gilead Sciences, Affidea, and Schoeller Allibert. He is recognized for driving financial and operational transformation across complex, multinational organizations. Most recently, Lynard served as CFO of Schoeller Allibert and Zentiva, a European pharmaceutical company [2].

Fabrice Chouraqui, Chief Executive Officer of Pharming, commented, "We are delighted to welcome Kenneth to Pharming at a pivotal stage in our growth. Kenneth brings broad finance leadership capabilities from both established industry leaders and dynamic growth-stage companies, and operational experience in both the U.S. and EU. His strong value creation mindset, shaped by experience with companies backed by leading private equity firms, will be extremely valuable as we continue to advance our vision of building a leading global rare disease company."

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific [1].

Lynard commented, "I’m excited to join Pharming at such a pivotal moment in its evolution. The company’s strong growth momentum, combined with upcoming commercial and pipeline catalysts, reflects a solid foundation for long-term success. As the new Chief Financial Officer, I look forward to strengthening the foundations to enable continued operational efficiency and support sustainable value creation. What truly inspires me, however, is Pharming’s deep commitment to patients, especially those with few or no treatment options, and often unaware they are living with a rare disease. That purpose-driven mission is what makes this opportunity so meaningful."

References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142312/0/en/Pharming-Group-appoints-Kenneth-Lynard-as-Chief-Financial-Officer.html
[2] https://www.morningstar.com/news/globe-newswire/1001125782/pharming-group-appoints-kenneth-lynard-as-chief-financial-officer